Helen Gall

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

Jan B. Vermorken, A.M.E. Claessen, Harm van Tinteren et al. · The Lancet · 1999 · 503 citations · Full text

Medicine, Immunology, Oncology +10

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Alfons JM van den Eertwegh, Jurjen Versluis, H. Pieter van den Berg et al. · The Lancet Oncology · 2012 · 357 citations

Medicine, Immunology, Oncology +16

Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors

Cees J. van Groeningen, Godefridus J. Peters, Jan H. Schornagel et al. · Journal of Clinical Oncology · 2000 · 158 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Saskia J. Santegoets, Anita G.M. Stam, Sinéad M. Lougheed et al. · Journal for ImmunoTherapy of Cancer · 2014 · 106 citations · Full text

Medicine, Immunology, Oncology +17

T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Saskia J. Santegoets, Anita G.M. Stam, Sinéad M. Lougheed et al. · Cancer Immunology Immunotherapy · 2012 · 91 citations · Full text

Medicine, Immunology, Oncology +16